Trials / Sponsors / Gamida Cell ltd

Gamida Cell ltd

Industry · 8 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refracto Non-Hodgkin Lymphoma	Phase 1 / Phase 2	2022-07-05
Completed	Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies Hematological Malignancies	Phase 3	2020-07-08
Completed	Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and M Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)	Phase 3	2016-12-16
Terminated	Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies Sickle Cell Disease, Thalassemia	Phase 1 / Phase 2	2016-04-04
Completed	Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients Patients Transplanted With NiCord/CordIn (Omidubicel)	—	2014-05-01
Completed	Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)	Phase 1 / Phase 2	2013-04-01
Completed	Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobin Sickle Cell Disease & Thalassemia	Phase 1 / Phase 2	2012-09-01
Completed	Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancie Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)	Phase 1 / Phase 2	2010-11-01